Global TROP2 Antibody Market & Clinical Trials Insight Research Report 2021-2026 –

DUBLIN – (COMMERCIAL THREAD) – The report “Global TROP2 Antibody Market & Clinical Trials Insight 2026” has been added to offer.

The global market for drugs targeting Trop2 is expected to exceed US $ 4 billion by 2026.

The increasing prevalence of cancer in all geographies, the high demand for targeted therapies for the treatment of cancer, favorable reimbursement policies offered by manufacturers and insurers, and increased awareness of the drug targeting Trop-2 due to of its high efficiency will propel the market growth.

Additionally, increasing geriatric population and increasing technological advancements in cancer screening and diagnosis are complementing the market growth.

The major players in the TROP2 antibody market are Daiichi Sankyo, Immunomedics, Gilead Sciences, AstraZeneca, Pfizer, BioThera Solution and others. The main market players have adopted strategic alliances such as collaborations, partnerships or joint ventures to meet the high costs of research and development and to maintain their market share.

For example, Daiichi Sankyo and AstraZeneca recently announced a second trial collaboration with Merck to evaluate the combination of datopotamab deruxtecan (Dato-DXd), a DXd antibody-drug conjugate driven by TROP2 and Keytruda in lung cancer patients. not with small cells.

Studies have also shown that Trop2 is highly expressed on several cancer cells and is generally associated with its aggressive nature. Apart from this, it is also involved in several signaling pathways which ultimately lead to the growth and proliferation of cancer cells. Therefore, targeting Trop2 may be an alternative to target cancer.

Recently, scientists have developed a new antibody-drug conjugate in which the therapeutic antibody is targeted to Trop2, thereby delivering the cytotoxin to the surface of the tumor cell. Sacituzumab govitecan-hziy (Trodelvy) developed by Immunomedics is the first trop2 targeted antibody-drug conjugate approved for patients with locally advanced unresectable triple negative breast cancer (mTNBC) who have received at least two treatments systemic disease, at least one of them for metastatic disease.

The introduction of Trodelvy in 2020 is expected to experience high growth rates in the market due to the lack of effective targeted therapies in mTNBC. It is believed that Trodelvy will revolutionize the overall treatment of TNBC and dramatically improve survival outcomes.

Beyond the approval of Trodelvy in the United States, it has also obtained approval in Australia, Canada, United Kingdom and Switzerland for adults with metastatic TNBC. Apart from that, the drug is present for regulatory view in other regions, notably in Europe, China and Singapore.

Recently, the European Medicines Agency recommended the marketing of Trodelvy, indicating that the medicine will enter the market in the coming months. The rapid approval of the drug in different regions will fuel the growth of the market in the years to come.

Trodelvy’s early approval has boosted innovation and development in this sector. To date, a drug cocktail targeted by Trop2 including DS-1062a, RN927C, BAT8003, SKB264, JS108 is present in clinical development.

These drugs have been designed to target a wide range of cancers, including non-small cell lung cancer, epithelial cancer, skin cancer, colon cancer, and others.

Apart from this, several experimental studies are also underway to assess the efficacy of Trodelvy in the treatment of hormone receptor positive / human epidermal growth factor receptor 2 negative (HR + / HER2-) metastatic breast cancer and cancer. metastatic non-small cell lung. . Additional evaluation on several solid tumors is also underway. The coming years will see a rapid influx of Trop-2 targeted therapies in a wide range of cancers.

Global TROP2 Antibodies and Insight Clinical Trials Market Report 2026 Analysis and Data Highlights:

  • Research methodology

  • Global and regional market analysis

  • Global TROP2 Antibody Market Opportunity Assessment:> USD 4 Billion

  • Overview of Drug Market and Sales from 2020 to 2026

  • Drug approved on the market: 1 drugs

  • TROP2 Antibody Patent Approved, 2020 Price and Sales Overview to 2026

  • Future market assessment by indication until 2026

  • Assessment of ongoing clinical trials by status, phase and region

  • Key market dynamics

  • Competition landscape

Main topics covered:

1. Market Introduction of TROP2 Targeting Therapy

1.1 Overview

1.2 History of TROP2 Targeting Therapies

2. TROP2 Ideal clinical biomarker for cancer

3. Therapeutic Targeting Mechanism of TROP2

4. Global TROP2 Targeting Therapy Market Analysis

4.1 Current market scenario

4.2 Future market opportunity

5. Global TROP2 Targeting Therapy Market Opportunity by Region

5.1 United States

5.2 Europe

5.3 Japan

5.4 Rest of the world

6. Global Targeting TROP2 Cancer Therapies Market

6.1 Breast cancer

6.2 Urothelial carcinoma

6.3 Lung cancer

6.4 Pancreatic cancer

6.5 Prostate cancer

7. First approved TRO2 targeting antibody – Trodelvy (Sacituzumab Govitecan)

7.1 Overview

7.2 Approval, patent and exclusivity

8. Trodelvy – Commercial information

8.1 Dosage and Price Analysis

8.2 Sales analysis

9. Trodelvy sales forecast 2026

10. Overview of Clinical Trials of TROP2 Targeted Therapy

10.1 By phase

10.2 By development status

10.3 By region

11. Global TROP2 Targeting Therapy Market – Ongoing Research and Development

11.1 Datopotamab Deruxtecan (DS-1062)

11.2 SKB264

11.3 JS108

11.4 MTD 8003

11.5 Trodelvy (Sacituzumab Govitecan)

12. Global Targeted Therapies TROP2 Market Dynamics

12.1 Market drivers

12.2 Market challenges

13. Future Outlook of the Global TROP2 Targeting Therapy Market

14. Competitive landscape

14.1 Amunix

14.2 ARIUS search

14.3 AstraZeneca

14.4 Biothera

14.5 Daiichi Sankyo Company

14.6 Gilead

14.7 Immunomedicine

14.8 Janux therapy

14.9 Klus Pharma

14.10 Myeloid therapy

14.11 Pfizer Inc

14.12 Shanghai Junshi Biosciences

For more information on this report, visit

Comments are closed.